Apply to USF Now | Graduate Admissions | Events & Workshops | Giving to the Office of Graduate Studies

Graduate Course Proposal Form Submission Detail - PHC7122

Edit function not enabled for this course.

Current Status: Approved, Permanent Archive - 2011-06-30
Campus: Tampa
Submission Type: New
Course Change Information (for course changes only):
Comments: to GC for review; 2/15/11 -descr too long - corrected. To GC 3/11/1. Apprd 3/21/11. to System 3/24/11. To SCNS 4/1/11. SCNS approved effe. 5/15/11. nmbr 7935 chnged to 7122

  1. Department and Contact Information

    Tracking Number Date & Time Submitted
    2360 2010-07-19
    Department College Budget Account Number
    Global Health PH
    Contact Person Phone Email
    Ricardo Izurieta 813 9748913

  2. Course Information

    Prefix Number Full Title
    PHC 7122 Vaccinology

    Is the course title variable? N
    Is a permit required for registration? Y
    Are the credit hours variable? N
    Is this course repeatable?
    If repeatable, how many times? 0

    Credit Hours Section Type Grading Option
    3 C - Class Lecture (Primarily) R - Regular
    Abbreviated Title (30 characters maximum)
    Course Online? Percentage Online
    C - Face-to-face (0% online) 0


    Graduate or undergradute immunology course


    Course Description

    Provides advanced information regarding the current state of vaccinology. Besides currently available vaccines, the course reviews vaccines under experimentation for emerging and re-emerging diseases as well as vaccines for neglected tropical diseases.

  3. Justification

    A. Please briefly explain why it is necessary and/or desirable to add this course.

    Needed to compete with national trends

    B. What is the need or demand for this course? (Indicate if this course is part of a required sequence in the major.) What other programs would this course service?

    Worldwide, vaccines have been descibed as one of the most effective Public Helath interventions and one of the best achievements in the history of human's health.

    C. Has this course been offered as Selected Topics/Experimental Topics course? If yes, how many times?

    D. What qualifications for training and/or experience are necessary to teach this course? (List minimum qualifications for the instructor.)

    Doctorate in Global or Internation Health with clinical experience at the national or international level.

  4. Other Course Information

    A. Objectives

    To provide students with an advanced knowledge of the pathogenesis, the epidemiology and the immunology of vaccine-preventable diseases, highlighting the strengths and limitations of each type of vaccine.

    To facilitate understanding the principles of implementing immunization programs for emerging and tropical neglected diseases. To enable students to analyze new public health strategies concerning vaccine preventable diseases in developed and developing countries.

    B. Learning Outcomes

    1. To know the characteristics of the main vaccines recommended by the Centers for Disease Control and Prevention as well as vaccines used for special populations.

    2 To critically analyze new vaccines included in the Centers for Disease Control Vaccines List as well as new vaccines for neglected diseases.

    3. To be able to analyze and design immunization programs and strategies.

    C. Major Topics

    1.Vaccines as a Practical Tool in Public Health: Smallpox and Jenner, Polio and Salk, and Worldwide Eradication

    2.Vaccination Principles, Basic Immunology and Herd Immunity

    3. Measles, Mumps and Rubella (MMR)

    4. Diphtheria, Tetanus, and Pertussis

    5. Oral Polio & Inactivated Polio

    6. Haemophilus influenza type B

    7. Hepatitis B

    8. BCG

    9. Pneumococcus



    12.Hepatitis A

    13.Meningococcal Disease

    14.Vaccines in Development for HIV

    15.Human Papilloma Virus


    17.Yellow Fever

    18.Vaccines in Development for Tropical Neglected Infections: Malaria and Dengue

    19. Vaccine Delivery: General Immunization practices

    20. Vaccine Regulation: Testing, Manufacturing, Safety, and Quality Control

    D. Textbooks

    S Plotkin, W. Oreinstein, and P. Offit (2008), Vaccines. Fifth Edition. China: Elsviere. ISBN 978-1-4160-3611-1

    Atkinson W, et al. (eds.): Epidemiology and Prevention of Vaccine-Preventable Diseases. Washington, DC: DHHS (CDC), Eleventh edition, May 2009, (Health Sciences Bookstore, or internet)

    Journal papers and documents included in this syllabus

    Required readings are available through the copy room at COPH. Several articles per week will be required in addition to selections from the required texts above. I

    E. Course Readings, Online Resources, and Other Purchases

    • WHO (2009) Global Polio Eradication Strategies. World Health Organization.

    Retrieved from:

    • Roush SW, Murphy TV; Vaccine-Preventable Disease Table Working Group (2007). Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. Nov 14;298(18):2155-63.

    • Duclos P, Okwo-Bele JM, Gacic-Dobo M, Cherian T (2009) Global immunization: status, progress, challenges and future BMC International Health and Human Rights, 9(Suppl 1):S2

    Retrieved from:

    • WHO Advisory Committee on Poliomyelitis Eradication (2009) Recommendations on the use of bivalent oral poliovirus vaccine types 1 and 3, World Health Organization.

    Retrieved from:

    • Hull HF (2001). The future of polio eradication. Lancet Infect Dis. Dec;1(5):299-303

    Retrieved from:

    • Abbas MB (1983). The Smallpox Story: Life and Death of an Old Disease. Microbiological Reviews pp 455-509

    Retrieved from:

    • Cutts FT, Henao-Restrepo A, Olive JM (1999). Measles elimination: progress and challenges. Vaccine. 17 Suppl 3:S47-52,

    Retrieved from:

    • Baker J. & Katz S (2004).Childhood Vaccine Development: An Overview Pediatric Research 55 (2):347-56

    • National Institutes of Health (2008). Understanding Vaccines. Washington, DC: NIAID Science Education.

    • PAHO (2007). Vaccine Preventable Diseases. In Health in the Americas. Volume 1 pages 83-98. Pan American Health Organization

    • Miller E. (2002) MMR vaccine: a review of benefits and risks. Infect. 44(1):1-6.

    • Sengupta N, Bedford H, Elliman D, Booy R, (2004). Does the MMR triple vaccine cause autism?. Evidence-Based Healthcare & Public Health 8, 239–245

    • Aylward RB, Clements J, Olive JM (1997). The impact of immunization control activities on measles outbreaks in middle and low income countries. Int J Epidemiol 26(3): 662-9

    • Hirshon JM, Irons B, Figueroa P, et al. (1999). Jamaica's Measles Elimination Experience. Am J Public Health Vol 89(8): 1254-5

    • Plosker GL (2009). Combined, Reduced-Antigen Content Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Boostrix(R))+: A Review of its Use as a Single-Dose Booster Immunization in Individuals Aged 10-64 Years in the US. BioDrugs: Vol 23 (4) pp. 253-267

    Retrieved from:

    • Adalja A (2009).Tetanus-Diphtheria-Acellular Pertussis (Tdap): TAP The Resources of The Emergency Department to Fight Pertussis The Journal of Emergency Medicine (Article in Press)

    Retrieved from:

    • Pickering L K (2009).Immunization Programs for Infants, Children, Adolescents, and Adults: Clinical Practice Guidelines by the Infectious Diseases Society of America. CID 2009:49 (15 September) pp 817-840 Retrieved from:

    • MMWR 1995; 44: 177-81. Diphtheria epidemic-New independent states of the former Soviet Union, 1990-1994. JAMA 273(16): 1250-51, 1995. MMWR 1995; 44: 237, 243-244. Weekly epidemiological record

    • Status of neonatal tetanus Elimination in the United Republic of Tanzania – results from a lot quality-assurance cluster survey. 29, 2009, 84, 289–300

    • Hitchcock WP (2006).Rationale for Use of Tdap Booster Vaccines for Adolescent Immunization: Overview of Efficacy, Safety, and Clinical Use. Clinical Pediatrics 45 pp. 785-794

    Retrieved from:

    • Pan American Health Organization (2006). Poliomyelitis Erradication Field Guide. Third Edition. Washington, DC. World Health Organization/Pan American Health Organization.

    • Cochi SL, Kew O (2008). Polio Today: Are We on the Verge of Global Erradication? JAMA. 300(7):839-841

    Retrieved from:

    • Galil K, Singleton R, Levine O, et al. (1999). J Infect Dis 179 pp:101-6.

    Reemergence of Invasive Haemophilus influenzae Type b Disease in a Well-Vaccinated Population in Remote Alaska.

    • Cowgill KD, Ndiritu M, Nyiro J, Slack MP, Chiphatsi S, Ismail A, Kamau T, Mwangi I, English M, Newton CR, Feikin DR, Scott JA (2006). Effectiveness of Haemophilus influenzae type b Conjugate vaccine introduction into routine childhood immunization in Kenya. JAMA. 296(6) pp. 671-8.

    • Centers for Disease Control (2002). Progress Toward Elimination of Haemophilus influenzae Type b Invasive Disease Among Infants and Children—United States, 1998-2000 JAMA 287(17) pp.2206-7.

    • Heath PT, McVernon J (2002). The UK Hib vaccine experience. Arch Dis Child 86 pp: 396-399.

    • CDC (2007). Progress Towards Poliomyelitis Eradication India, January 2006–September 2007. MMWR News Synopsis for November 15, 200.

    Retrieved from:

    • Beasley RP (2009). Development of Hepatitis B Vaccine. JAMA. 302(3) pp.322-324

    • Zanetti AR, Van Damme P, Shouval D (2008).The global impact of vaccination against hepatitis B: A historical overview. Vaccine. 26(49) pp. 6266-73

    • Hepatitis Foundation International. The ABC's of Hepatitis.

    • Hall A. We have a cancer vaccine- why don't we use it? Trop Med Inter Health 3(5): 337-8, 1998.

    • Hilleman MR (2003).Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine 21(32) pp:4626-49.

    • Hewinson RG. (2005). TB vaccines for the World. Tuberculosis (Edinb) 85(1-2) pp:1-6.

    • Barreto ML, Pereira SM, Ferreira AA (2006). BCG vaccine: efficacy and indications for vaccination and revaccination J Pediatr (Rio J) 82(3 Suppl):S45-54

    • Rodrigues LC, Kerr-Pontes LR, Frietas MV, Barreto ML (2007). Long lasting BCG protection against leprosy. Vaccine 25(39-40) pp: 6842-4.

    • CDC (1998). Development of new vaccines for Tuberculosis: Recommendations of the Advisory Council for the elimination of tuberculosis (ACET). MMWR 47(RR-13) pp:1-6

    • Fine PE (2001). BCG: the challenge continues. Scand J Infect Dis. 33(4):243-5. Review.

    • Lεng H, Quaglio GL, Olesen OF (2009). Tuberculosis research in the European Union: Past achievements and future challenges. Tuberculosis October Issue in Press pp:1–6

    • Ellner JJ (1997). Review: The immune response in human tuberculosis-Implications for tuberculosis control. J Infect Dis 176: 1351-9.

    • Oosterhuis-Kafeja F, Beutels P, Van Damme P (2007). Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine. 25(12) pp:2194-212

    • Nuorti JP, Butler JC, Crutcher JM, Guevara R, Welch D, Holder P, Elliott JA. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med 338(26): 1861-68, 1998.

    • Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M, Takahashi K, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Yamashita M, Mitamura K, Nakano K, Nakamura M, Brockman-Schneider R, Mitamura H, Yamazaki M, Sugaya N, Suresh M, Ozawa M, Neumann G, Gern J, Kida H, Ogasawara K, Kawaoka Y (2009).In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 460(7258):1021-5.

    • Couch RB, Keitel WA, Cate TR (1997). Improvement of inactivated influenza virus vaccines. J Infect Dis 176(Supp1) pp: 38-44

    • Neustadt RE and Fineberg H (1986). Chapter 1:The new flu, Chapter 2: Sencer decides In: The epidemic that never was: Policy-making and the swine flu affair. Vintage books, a division of Random House, New York, first edition pp:17-31

    • Ropero-Αlvarez A, Kurtis H, Danovaro-

    Holliday M, Ruiz-Matus C, Andrus J (2009). Expansion of seasonal influenza vaccination in the Americas. BMC Public Health 9:361

    • Marshall GS (2009).Rotavirus disease and prevention through vaccination. Pediatr Infect Dis J. 28(4):355-62.

    • Patel MM, Haber P, Baggs J, Zuber P, Bines JE, Parashar UD (2009). Intussusception and rotavirus vaccination: a review of the available evidence. Expert Rev Vaccines. 8(11) pp:1555-64.

    • Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, Gonzalez A, Malespin O, Amador JJ, Umaρa J, Balmaseda A, Perez MC, Gentsch J, Kerin T, Hull J, Mijatovic S, Andrus J, Parashar U (2009).Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA. 301(21):2243-51

    • Bresee JS. Glass RI. Ivanoff B. Gentsch JR (1999). Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine. 17(18) pp: 2207-2222

    • Intussusception Among Recipients of Rotavirus Vaccine -- United States, 1998-1999 MMWR Weekly July 16, 1999 / 48(27); 577-581.

    • Gupta A, Chawla Y (2008).Changing epidemiology of hepatitis A infection. Indian J Med Res. 128(1):7-9.

    • Koslap-Petraco MB, Shub M, Judelsohn R.(2008).Hepatitis A: disease burden and current childhood vaccination strategies in the United States. J Pediatr Health Care. 22(1):3-11.

    • Wildes SS, Tunkel AR (2002). Meningococcal vaccines: a progress report. BioDrugs. 16(5) pp:321-329.

    • Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease (2009). Vaccine.;27 Suppl 2 pp:B51-63

    • Cassis-Ghawami F, Curlin M, Geise R, Duerr A (2009). Human Immunodeficiency Virus. In Vaccines for Biodefense and Emerging and Neglected Diseases by A Barret and L Stanberry. Elsevier, London, UK pp:441-467

    • Letvin NL. Strategies for an HIV vaccine (2002). J Clin Invest. Jul;110(1) pp:15-20.

    • Miedema F (2008).A brief history of HIV vaccine research: stepping back to the drawing board? AIDS. Sep 12;22(14) pp:1699-703.

    • Auerbach JD, Hayes RJ, Kandathil SM (2006). Overview of effective and promising interventions to prevent HIV infection. World Health Organ Tech Rep Ser. ;938:43-78; discussion 317-41.

    • Veljkovic V, Kφhler H, Mόller S (2004). AIDS vaccine: state of the art at the beginning of the third millennium. Int Rev Immunol. Sep-Dec;23(5-6):369-81.

    • Francis DP, Heyward WL, Popovic V et al (2003). Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials. AIDS. 17(2) pp:147-56.

    • HIV Vaccine Trials Network.

    • Rogers LJ, Eva LJ, Luesley DM (2008). Vaccines against cervical cancer. Curr Opin Oncol. Sep; 20(5) pp:570-4.

    • Dunne EF, Datta SD, E Markowitz L (2008). A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. Cancer. Nov 15;113(10 Suppl) pp:2995-3003.

    • Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ (2008). Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. Aug 19;26 Suppl 10 pp:K29-41.

    • Zussman J, Young L (2008). Zoster vaccine live for the prevention of shingles in the elderly patient. Clin Interv Aging. 3(2) pp:241-50.

    • Takahashi M (2001). 25 years' experience with the Biken Oka strain varicella vaccine: a clinical overview. Paediatr Drugs. 3(4) pp:285-92.

    • Parmet S, Lynm C, Glass RM (2004). JAMA patient page. Chickenpox. JAMA. Feb 18;291(7) pp:906.

    • Galbraith S,Barret A (2009). Chapter 40: Yellow Fever. In A. Barret and L. Stanberry (Eds.), Vaccines for Emerging and Neglected Diseases (pp. 858-885). London, UK: Elseviere.

    • Izurieta R, Macaluso M, Watts D, Tesh R, Guerra B, Cruz LM, Galwankar S, Vermund S. (2009). Assessing yellow fever risk in the Ecuadorian Amazon. Journal of Global Infectious Diseases 1 (1) pp: 7-13;year=2009;volume=1;issue=1;spage=7;epage=13;aulast=Izurieta;type=0

    • Centers for Disease Control and Prevention (2009). What You Need to Know About Vaccinations and Travel: A Checklist

    • YF Endemic Zones (2010):

    • Typhoid:

    • Japanese Encephalitis (2010):

    • Cholera (2010):

    • Rabies (2010):

    • Plaque (2010):

    • Policies for International Travel (2010):

    • Vaughn DW, Whitehead S, Durbin A (2009). Chapter 19: Dengue. In A. Barret and L.Stanberry (Eds.), Vaccines for Emerging and Neglected Diseases (pp. 858-885). London, UK:Elseviere.

    • Richie T, Parekh F (2009). Chapter 65: Malaria. In A. Barret and L.Stanberry (Eds.), Vaccines for Emerging and Neglected Diseases (pp. 858-885). London, UK:Elseviere.

    • Webster DP, Farrar J, Rowland-Jones S (2009). Progress towards a dengue vaccine. Lancet Infect Dis. Nov; 9(11) pp:678-87.

    • Tuteja R (2007). Malaria - an overview. FEBS J. Sep;274(18) pp:4670-4679.

    • Hoffman SL. Rogers WO. Carucci DJ. Venter JC (1998). From genomics to vaccines: malaria as a model system. Nature Medicine. Dec. 4(12) pp: 1351-1353.

    Hampton T (2004). Malaria vaccine shows promise. JAMA. Dec 8;292(22) pp:2703-2704.

    • Vaughn DW, Whitehead S, Durbin A. (2009). Chapter 4: Vaccine Development Pathway. In A. Barret and L.Stanberry (Eds.), Vaccines for Emerging and Neglected Diseases (pp. 45-54). London, UK:Elseviere.

    • Baylor N, Midthun K (2008). Chapter 73: Regulation and Testing of Vaccines,. In S Plotkin, W. Oreinstein, and P. Offit (Eds.), Vaccines (pp. 1611-1627). China: Elsviere.

    • Myers M, Pineda D (2009). Chapter 17: Misinformation about vaccines. In A. Barret and L.Stanberry (Eds.), Vaccines for Emerging and Neglected Diseases (pp. 45-54). London, UK:Elseviere.

    • Huot C, Sauvageau C, Tremblay G, Dubι E, Ouakki M (2010). Adult immunization services: Steps have to be done. Vaccine.. [Epub ahead of print]

    F. Student Expectations/Requirements and Grading Policy

    Mid-term – 35%

    Final Exam - 25%

    Essay - 20%

    Power Point Presentation - 20%

    G. Assignments, Exams and Tests

    Mid-term – 35%

    Final Exam - 25%

    The mid-term and final exams will consist of essay questions.

    Essay - 20%

    There will be a 10 pages essay relate to new vaccines for emerging and reemerging diseases as well as tropical neglected diseases. Papers should be double spaced typed, containing at least 10 references.

    Power Point Presentation - 20%

    The power point presentation will be no more than 15 minutes (No more than 15 slides) to be given to a target audience on an experimental vaccine.



     Plague vaccine

     Rabies vaccine

     Anthrax vaccine use in the military

     Japanese B encephalitis Vaccine

     Brucellosis Vaccine

     Chlamydia vaccine

     Oral typhoid vaccine

     Botulinum toxin

     Gonorrhea vaccine

     Syphilis vaccine

     Helicobacter pylori vaccine

     New vaccine approaches for TB

     West Nile Virus vaccines

     Vaccines for Ebola

     Vaccines for Schistosomiasis

     Line disease vaccine

     Lassa Fever vaccine

     Vaccines for Eastern Equine Encephalitis

     African Trypanosomiasis vaccine

     Leishmania vaccine

     Leptospirosis vaccine

     Hookworm vaccine

     Onchocerciasis vaccine

     Chagas disease vaccine

    H. Attendance Policy

    Course Attendance at First Class Meeting – Policy for Graduate Students: For structured courses, 6000 and above, the College/Campus Dean will set the first-day class attendance requirement. Check with the College for specific information. This policy is not applicable to courses in the following categories: Educational Outreach, Open University (TV), FEEDS Program, Community Experiential Learning (CEL), Cooperative Education Training, and courses that do not have regularly scheduled meeting days/times (such as, directed reading/research or study, individual research, thesis, dissertation, internship, practica, etc.). Students are responsible for dropping undesired courses in these categories by the 5th day of classes to avoid fee liability and academic penalty. (See USF Regulation – Registration - 4.0101,

    Attendance Policy for the Observance of Religious Days by Students: In accordance with Sections 1006.53 and 1001.74(10)(g) Florida Statutes and Board of Governors Regulation 6C-6.0115, the University of South Florida (University/USF) has established the following policy regarding religious observances: (

    In the event of an emergency, it may be necessary for USF to suspend normal operations. During this time, USF may opt to continue delivery of instruction through methods that include but are not limited to: Blackboard, Elluminate, Skype, and email messaging and/or an alternate schedule. It’s the responsibility of the student to monitor Blackboard site for each class for course specific communication, and the main USF, College, and department websites, emails, and MoBull messages for important general information.

    I. Policy on Make-up Work

    J. Program This Course Supports

    Global Health PhD and DrPH

  5. Course Concurrence Information

    PhD programs in the College of Public Health

    PhD programs in the College of Nursing

    MD program in College of Medicine

    PhD programs in other Colleges or Schools, like Pharmacy

- if you have questions about any of these fields, please contact or